新型自动智能吸引装置(VapCare)在机械通气神经重症患者中的安全性与有效性:一项前瞻性随机试验
该单中心、开放标签随机试验纳入需机械通气48小时或以上的成人神经重症患者,排除气管切开、出血性疾病、困难气道或已存在肺炎者,比较VapCare管理组与标准ICU护理(手动口咽吸引)组从第1天到第5天的肺超声评分、临床肺部感染评分、分泌物量、气管培养及胸部X线结果。VapCare组临床肺部感染评分中位数从第1天1分(四分位距1-2)升至第5天3分(四分位距2-3),对照组从1分(四分位距1-2)升至5分(四分位距2.75-6)(p<0.001);肺超声评分VapCare组从0分(四分位距1-2)升至4分(四分位距2-6),对照组从0分(四分位距0-2)升至6分(四分位距2-10)(p<0.001);VapCare组胸部X线评分更低(p=0.028),ICU住院时间显著更短(p=0.004)。气管培养微生物生长与死亡率两组相似;VapCare组1例因口含件致唇部黏膜糜烂。
要点
- VapCare组第5天临床肺部感染评分中位数3分(四分位距2-3),低于对照组5分(四分位距2.75-6),p<0.001。
- VapCare组第5天肺超声评分中位数4分(四分位距2-6),低于对照组6分(四分位距2-10),p<0.001。
- VapCare组胸部X线评分低于对照组(p=0.028),ICU住院时间显著更短(p=0.004)。
- 气管培养微生物生长与死亡率两组相似,差异无统计学意义。
- VapCare组1例因口含件发生唇部黏膜糜烂。
适用人群与场景
- 成人神经重症监护患者,需机械通气48小时或以上。
- 排除气管切开患者、出血性疾病患者、困难气道患者及已存在肺炎患者。
处置流程与药物剂量
- 对照组接受标准ICU护理,包括手动口咽吸引。
- 研究组接受VapCare自动分泌物管理装置管理。
研究设计与关键结果
- 单中心、开放标签随机试验,纳入成人神经重症需机械通气48小时或以上患者,排除气管切开、出血性疾病、困难气道或已存在肺炎者。
- 主要比较第1天至第5天肺超声评分、临床肺部感染评分、分泌物量、气管培养及胸部X线结果。
- 临床肺部感染评分中位数:对照组第1天1分(四分位距1-2)升至第5天5分(四分位距2.75-6),VapCare组第1天1分(四分位距0-2)升至第5天3分(四分位距2-3),p<0.001。
- 肺超声评分中位数:对照组第1天0分(四分位距0-2)升至第5天6分(四分位距2-10),VapCare组第1天0分(四分位距1-2)升至第5天4分(四分位距2-6),p<0.001。
- 胸部X线评分VapCare组更低(p=0.028)。
- 气管培养微生物生长与死亡率两组相似;ICU住院时间VapCare组显著更短(p=0.004)。
- VapCare组1例因VapCare口含件发生唇部黏膜糜烂。
证据类型、等级与局限
- 证据类型:单中心、开放标签随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在需机械通气48小时或以上的成人神经重症患者中,VapCare装置可减缓临床肺部感染评分与肺超声评分的上升,并降低胸部X线评分。
- VapCare装置与更短的ICU住院时间相关(p=0.004),但气管培养微生物生长与死亡率与标准护理相似。
- 使用VapCare装置时需注意口含件可能导致唇部黏膜糜烂(VapCare组1例)。
- 作者认为该装置有效减少微误吸并减轻肺部改变,可能减轻机械通气患者微误吸与吸引负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) is a significant concern in intensive care units (ICUs), affecting 7-32% of mechanically ventilated patients, which mounts to higher morbidity and mortality and extended hospital stays. Preventing VAP involves meticulous secretion management and oral hygiene, but in low-resource settings, VAP remains common owing to the absence of standardized oral care protocols. This randomized study assessed the efficacy and safety of the VapCare automated secretion management device in reducing microaspirations and improving clinical outcomes in ventilated patients.
METHODS: A single-center, open-label randomized trial was conducted involving adult neurocritical care patients requiring mechanical ventilation for 48 h or more, excluding tracheostomized patients and patients with bleeding disorders, difficult airways, or preexisting pneumonia. Participants were randomly assigned to a control group, receiving standard ICU care with manual oropharyngeal suctioning, or a study group, receiving VapCare management. We compared lung ultrasound scores (LUS), clinical pulmonary infection scores (CPIS), secretion volumes, tracheal cultures, and chest X-ray results from day 1 to day 5.
RESULTS: The VapCare group demonstrated a slower rise in LUS and CPIS compared to the control group. The median CPIS rose from 1 (interquartile range [IQR] 1-2) on the first day to 5 (IQR 2.75-6) on the fifth day in the control group versus 1 (IQR 0-2) on the first day to 3 (IQR 2-3) on the fifth day in the VapCare group (p < 0.001). The median LUS increased from 0 (IQR 0-2) on the first day to 6 (IQR 2-10) on the fifth in the control group, whereas the change was more muted in the VapCare group (0 [IQR 1-2] on the first day to 4 [IQR 2-6] on the fifth day [p < 0.001]). Additionally, chest X-ray scores were lower in the VapCare group (p = 0.028). Tracheal culture microbial growth and mortality were similar in both groups, but the length of ICU stay was significantly shorter in the VapCare group (p = 0.004). One patient in the VapCare group sustained mucosal erosions on the lip due to the VapCare mouthpiece.
CONCLUSIONS: The VapCare device effectively reduces microaspiration and mitigates lung changes, demonstrating its potential to reduce the burden of microaspiration and suctioning in ventilated patients.
参考来源
- Varnitha MS, Murlidhara P, Sharma A, et al. Safety and Efficacy of a Novel Automated Intelligent Suction Device (VapCare) Among Mechanically Ventilated Neurocritical Care Patients: A Prospective Randomized Trial. Neurocrit Care. 2025. PMID: 40214890. doi:10.1007/s12028-025-02253-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。